Cargando…

Drug resistance and minimal residual disease in multiple myeloma

Great progress has been made in improving survival in multiple myeloma (MM) patients over the last 30 years. New drugs have been introduced and complete responses are frequently seen. However, the majority of MM patients do experience a relapse at a variable time after treatment, and ultimately the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gozzetti, Alessandro, Ciofini, Sara, Sicuranza, Anna, Pacelli, Paola, Raspadori, Donatella, Cencini, Emanuele, Tocci, Dania, Bocchia, Monica
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	OAE Publishing Inc. 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8992600/ https://www.ncbi.nlm.nih.gov/pubmed/35582527 http://dx.doi.org/10.20517/cdr.2021.116

Ejemplares similares

Minimal Residual Disease in Multiple Myeloma: State of the Art and Applications in Clinical Practice
por: Gozzetti, Alessandro, et al.
Publicado: (2020)

“Friends and foes” of multiple myeloma measurable/minimal residual disease evaluation by next generation flow
por: Pacelli, Paola, et al.
Publicado: (2022)

Anti CD38 monoclonal antibodies for multiple myeloma treatment
por: Gozzetti, Alessandro, et al.
Publicado: (2022)

Tumor-Associated Macrophages in Multiple Myeloma: Key Role in Disease Biology and Potential Therapeutic Implications
por: Cencini, Emanuele, et al.
Publicado: (2023)

Venetoclax in association with decitabine as effective bridge to transplant in a case of relapsed early T‐cell lymphoblastic leukemia
por: Zappone, Elisabetta, et al.
Publicado: (2020)

Long-Term Safety of Rapid Daratumumab Infusions in Multiple Myeloma Patients
por: Gozzetti, Alessandro, et al.
Publicado: (2020)

Anti-BCMA novel therapies for multiple myeloma
por: Sammartano, Vincenzo, et al.
Publicado: (2023)

Tp53 disruptions: is there a marker of poor prognosis in chronic lymphoproliferative disorders?
por: Cencini, Emanuele, et al.
Publicado: (2021)

Liquid biopsy and blood-based minimal residual disease evaluation in multiple myeloma
por: GOZZETTI, ALESSANDRO, et al.
Publicado: (2023)

The Role of Tumor-Associated Macrophages in Hematologic Malignancies
por: Cencini, Emanuele, et al.
Publicado: (2021)

CD26/DPP-4 in Chronic Myeloid Leukemia
por: Sicuranza, Anna, et al.
Publicado: (2022)

Steps towards a Multiple Myeloma Cure?
por: Gozzetti, Alessandro, et al.
Publicado: (2022)

Functional Imaging in the Evaluation of Treatment Response in Multiple Myeloma: The Role of PET-CT and MRI
por: Santoni, Adele, et al.
Publicado: (2022)

A BRAF-Negative Classic Hairy Cell Leukemia Patient with Long-Lasting Complete Remission after Rituximab and Pentostatin
por: Gozzetti, Alessandro, et al.
Publicado: (2020)

Therapeutic Advancements in Multiple Myeloma
por: Gozzetti, Alessandro, et al.
Publicado: (2014)

Minimal Residual Disease Detection at RNA and Leukemic Stem Cell (LSC) Levels: Comparison of RT-qPCR, d-PCR and CD26+ Stem Cell Measurements in Chronic Myeloid Leukemia (CML) Patients in Deep Molecular Response (DMR)
por: Abruzzese, Elisabetta, et al.
Publicado: (2023)

Prospective monitoring of chronic myeloid leukemia patients from the time of TKI discontinuation: the fate of peripheral blood CD26(+) leukemia stem cells
por: Pacelli, Paola, et al.
Publicado: (2023)

Daratumumab efficacy in extramedullary orbital myeloma
por: Gozzetti, Alessandro, et al.
Publicado: (2020)

Flow Cytometry Assessment of CD26(+) Leukemic Stem Cells in Peripheral Blood: A Simple and Rapid New Diagnostic Tool for Chronic Myeloid Leukemia
por: Raspadori, Donatella, et al.
Publicado: (2019)

Carfilzomib, lenalidomide, and dexamethasone in relapsed refractory multiple myeloma: a prospective real-life experience of the Regional Tuscan Myeloma Network
por: Antonioli, Elisabetta, et al.
Publicado: (2023)

Single Agent Lenalidomide Activity in Multiple Myeloma Relapse Evidenced Uniquely by CT/PET
por: Gozzetti, Alessandro, et al.
Publicado: (2012)

Real-Life Experience with Pomalidomide plus Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma: A Retrospective and Prospective Study
por: Del Giudice, Maria Livia, et al.
Publicado: (2021)

Identification of a Novel P190-Derived Breakpoint Peptide Suitable for Peptide Vaccine Therapeutic Approach in Ph+ Acute Lymphoblastic Leukemia Patients
por: Ippoliti, Micaela, et al.
Publicado: (2012)

P48 CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED REFRACTORY MULTIPLE MYELOMA: A PROSPECTIVE REAL-LIFE EXPERIENCE OF THE REGIONAL TUSCAN MYELOMA NETWORK (RTM)
por: Attucci, I., et al.
Publicado: (2023)

Residual Peripheral Blood CD26(+) Leukemic Stem Cells in Chronic Myeloid Leukemia Patients During TKI Therapy and During Treatment-Free Remission
por: Bocchia, Monica, et al.
Publicado: (2018)

Daratumumab in AL Amyloidosis: A Real-Life Experience of the “RTM” (Regional Tuscan Myeloma Network)
por: Sammartano, Vincenzo, et al.
Publicado: (2022)

Role of Imaging in the Evaluation of Minimal Residual Disease in Multiple Myeloma Patients
por: Zamagni, Elena, et al.
Publicado: (2020)

Carfilzomib plus dexamethasone in patients with relapsed and refractory multiple myeloma: A retro‐prospective observational study
por: Del Giudice, Maria Livia, et al.
Publicado: (2022)

Minimal residual disease in multiple myeloma: are we there yet?
por: Devarakonda, Srinivas, et al.
Publicado: (2020)

Minimal residual disease in multiple myeloma: current status
por: Ding, Hong, et al.
Publicado: (2021)

Role of lenalidomide in the treatment of peripheral T-cell non-Hodgkin lymphomas
por: Cencini, Emanuele, et al.
Publicado: (2021)

The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19
por: Gozzetti, Alessandro, et al.
Publicado: (2020)

Editorial: Molecular Mechanisms of Multiple Myeloma
por: Gozzetti, Alessandro, et al.
Publicado: (2022)

Overview of Anti-SARS-CoV-2 Immune Response Six Months after BNT162b2 mRNA Vaccine
por: Gandolfo, Claudia, et al.
Publicado: (2022)

Pro-Inflammatory and Pro-Oxidative Changes During Nilotinib Treatment in CML Patients: Results of a Prospective Multicenter Front-Line TKIs Study (KIARO Study)
por: Sicuranza, Anna, et al.
Publicado: (2022)

Minimal Residual Disease Assessment in the Context of Multiple Myeloma Treatment
por: Nishihori, Taiga, et al.
Publicado: (2016)

Minimal Residual Disease in Multiple Myeloma: Past, Present, and Future
por: Medina-Herrera, Alejandro, et al.
Publicado: (2023)

Primary CNS lymphoma: latest updates and a 10-year monocenter experience
por: Cencini, Emanuele, et al.
Publicado: (2018)

Lenalidomide and Temozolomide Combination in a Very Elderly Patient with CNS Relapse of Diffuse Large B-Cell Lymphoma
por: Cencini, Emanuele, et al.
Publicado: (2017)

Central Nervous System Myeloma and Unusual Extramedullary Localizations: Real Life Practical Guidance
por: Sammartano, Vincenzo, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_628oce7s2bi5r0srurgjdspvdp